Fed­er­al judge Kiyo Mat­sumo­to in a Brook­lyn court to­day sen­tenced Mar­tin Shkre­li to 7 years on three felony fraud con­vic­tions, end­ing a lengthy pub­lic spec­ta­cle in which the biotech ex­ec man­aged to re­peat­ed­ly en­rage the pub­lic over his drug pric­ing schemes. He was con­vict­ed, though, on charges re­lat­ed to ly­ing to in­vestors in his hedge funds.

Shkre­li’s at­tor­ney, Ben Braf­man, had waged a skill­ful cam­paign to guard the de­fi­ant young ex­ec, who, af­ter mak­ing bail, wound up back in prison await­ing sen­tenc­ing af­ter the judge was an­gered by Shkre­li’s bizarre of­fer of a $5,000 boun­ty on Hillary Clin­ton’s hair. The judge al­lowed 6 months cred­it for time served, leav­ing a long stretch for Shkre­li be­hind bars.

Min­utes be­fore the sen­tenc­ing, Braf­man ar­gued the gov­ern­ment’s re­quest for 15 years was in­ap­pro­pri­ate, call­ing it “dra­con­ian.” Braf­man said Shkre­li “may be bril­liant in cer­tain mat­ters,” but “lacks cer­tain so­cial skills.” He plead­ed with the judge not to rule harsh­ly on Shkre­li “just for be­ing Mar­tin Shkre­li.”

Mat­sumo­to as­sured Braf­man that Shkre­li’s so­cial me­dia pres­ence — and the mat­ter of drug pric­ing — were not is­sues for her.

“He be­haved re­spect­ful­ly in court,” she said.

In his wrap-up, Braf­man last­ly pled that the judge re­con­sid­er the lev­el of se­cu­ri­ty Shkre­li should be jailed in.

Def: When you sen­tence Mr. Shkre­li, it’s re­al prison. De­spite fact he some­times says stu­pid things. At end of day, he doesn’t be­long there, and doesn’t be­long there for sig­nif­i­cant amt of time. #PharmaBro #Shkre­li @wcbs880

— Ethan Harp (@EthanHarp­News) March 9, 2018

When the gov­ern­ment was up to lay its case against Shkre­li, they did it suc­cinct­ly.

Govt: Shkre­li is a con­vict­ed crim­i­nal, we didn’t say it was be­cause he was a lit­tle off or strange. He was con­vict­ed of 3 of 4 fraud schemes. #PharmaBro #Shkre­li @wcbs880

— Ethan Harp (@EthanHarp­News) March 9, 2018

In short, they called Shkre­li’s de­fense ab­surd, es­pe­cial­ly the part about spar­ing him for sci­ence’s sake.

Govt: This talk of him hav­ing po­ten­tial. A sig­nif­i­cant term in prison won’t de­ny the world of cures to child­hood dis­eases. #PharmaBro #Shkre­li @wcbs880

— Ethan Harp (@EthanHarp­News) March 9, 2018

Shkre­li him­self made his last state­ments, call­ing his con­duct both neg­li­gent and stu­pid.

#Shkre­li: “I still have work to do… I’m here bc of my gross, stu­pid neg­li­gent mis­takes I made at MSMB. This woul dbe a good time to apol­o­gize to all the in­vestors of MSMB.” His voice break­ing: “I’m ter­ri­bly sor­ry I lost your trust. You de­serve bet­ter.”

— Meg Tir­rell (@megtir­rell) March 9, 2018

#Shkre­li: There was no gov­ern­ment con­spir­a­cy to take down Mar­tin Shkre­li. I took down Mar­tin Shkre­li.

— Meg Tir­rell (@megtir­rell) March 9, 2018

Dur­ing the sen­tenc­ing, Mat­sumo­to said she as­sumed Shkre­li would ap­peal any sen­tence he was giv­en, and Braf­man con­firmed lat­er that he would ap­peal.

Im­age: Court­room sketch of Mar­tin Shkre­li and his lawyer Ben Braf­man. AP IM­AGES

When Venrock partner Bryan Roberts went to check the results from their annual survey of healthcare leaders, what he found was an imprint of the pandemic’s slow arrival in America.

The venture firm had sent their form out to hundreds of insurance and health tech executives, investors, officials and academics on February 24 and gave them two weeks to fill it out. No Americans had died at that point but the coronavirus had become enough of a global crisis that they included two questions about the virus, including “Total U.S. deaths in 2020 from the novel coronavirus will be:”.

Fabrice Chouraqui’s career has taken some big twists along his life journey. He got his PharmD at Université Paris Descartes and jumped into the drug development game for a bit. Then he took a sharp turn and went back to school to get his MBA at Insead before returning to pharma on the commercial side.

Twenty years later, after steadily rising through the ranks and journeying the globe to nab a top job as president of US pharma for the Basel-based Novartis, Chouraqui exited in another career switch. And now he’s headed into a hybrid position as a CEO-partner at Flagship, where he’ll take a shot at leading Cellarity — one of the VC’s latest paradigm-changing companies of the groundbreaking model that aspires to deliver a new platform to the world of drug R&D.